These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Floros KV; Cai J; Jacob S; Kurupi R; Fairchild CK; Shende M; Coon CM; Powell KM; Belvin BR; Hu B; Puchalapalli M; Ramamoorthy S; Swift K; Lewis JP; Dozmorov MG; Glod J; Koblinski JE; Boikos SA; Faber AC Cancer Res; 2021 Apr; 81(7):1896-1908. PubMed ID: 33483374 [No Abstract] [Full Text] [Related]
26. Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification. Wood L; Huang M; Zeki J; Gong M; Taylor J; Shimada H; Chiu B J Pediatr Surg; 2021 Jul; 56(7):1199-1202. PubMed ID: 33838899 [TBL] [Abstract][Full Text] [Related]
27. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma. Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426 [TBL] [Abstract][Full Text] [Related]
28. TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets. Decaesteker B; Denecker G; Van Neste C; Dolman EM; Van Loocke W; Gartlgruber M; Nunes C; De Vloed F; Depuydt P; Verboom K; Rombaut D; Loontiens S; De Wyn J; Kholosy WM; Koopmans B; Essing AHW; Herrmann C; Dreidax D; Durinck K; Deforce D; Van Nieuwerburgh F; Henssen A; Versteeg R; Boeva V; Schleiermacher G; van Nes J; Mestdagh P; Vanhauwaert S; Schulte JH; Westermann F; Molenaar JJ; De Preter K; Speleman F Nat Commun; 2018 Nov; 9(1):4866. PubMed ID: 30451831 [TBL] [Abstract][Full Text] [Related]
29. Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens. Rodríguez-Hernández CJ; Mateo-Lozano S; García M; Casalà C; Briansó F; Castrejón N; Rodríguez E; Suñol M; Carcaboso AM; Lavarino C; Mora J; de Torres C Oncotarget; 2016 Mar; 7(13):16112-29. PubMed ID: 26893368 [TBL] [Abstract][Full Text] [Related]
30. Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells. Veschi V; Petroni M; Cardinali B; Dominici C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Giannini G PLoS One; 2012; 7(11):e49139. PubMed ID: 23152863 [TBL] [Abstract][Full Text] [Related]
31. The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis. Kollareddy M; Sherrard A; Park JH; Szemes M; Gallacher K; Melegh Z; Oltean S; Michaelis M; Cinatl J; Kaidi A; Malik K Cancer Lett; 2017 Sep; 403():74-85. PubMed ID: 28602975 [TBL] [Abstract][Full Text] [Related]
32. DNA Ligase 4 Contributes to Cell Proliferation against DNA-PK Inhibition in Ando K; Suenaga Y; Kamijo T Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240360 [TBL] [Abstract][Full Text] [Related]
33. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines. Aygun N; Altungoz O Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774 [TBL] [Abstract][Full Text] [Related]
34. Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells. Horwacik I; Durbas M; Boratyn E; Węgrzyn P; Rokita H Cancer Lett; 2013 Dec; 341(2):248-64. PubMed ID: 23962557 [TBL] [Abstract][Full Text] [Related]
35. p53 is a direct transcriptional target of MYCN in neuroblastoma. Chen L; Iraci N; Gherardi S; Gamble LD; Wood KM; Perini G; Lunec J; Tweddle DA Cancer Res; 2010 Feb; 70(4):1377-88. PubMed ID: 20145147 [TBL] [Abstract][Full Text] [Related]
36. S(+)-ibuprofen destabilizes MYC/MYCN and AKT, increases p53 expression, and induces unfolded protein response and favorable phenotype in neuroblastoma cell lines. Ikegaki N; Hicks SL; Regan PL; Jacobs J; Jumbo AS; Leonhardt P; Rappaport EF; Tang XX Int J Oncol; 2014 Jan; 44(1):35-43. PubMed ID: 24173829 [TBL] [Abstract][Full Text] [Related]
37. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression. Carr-Wilkinson J; Griffiths R; Elston R; Gamble LD; Goranov B; Redfern CP; Lunec J; Tweddle DA Cell Cycle; 2011 Nov; 10(21):3778-87. PubMed ID: 22052359 [TBL] [Abstract][Full Text] [Related]
38. Deficiency of BAP1 inhibits neuroblastoma tumorigenesis through destabilization of MYCN. Zhang X; Cong X; Jin X; Liu Y; Zhang T; Fan X; Shi X; Zhang X; Wang X; Yang YG; Dai X Cell Death Dis; 2023 Aug; 14(8):504. PubMed ID: 37543638 [TBL] [Abstract][Full Text] [Related]
39. Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092 [TBL] [Abstract][Full Text] [Related]
40. Direct Targeting of Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]